ARF1 and breast cancer: In a recent study, it was discovered that pyroptosis of fewer than 15% of tumor cells was adequate to eradicate the entire grafted 4T1 mammary tumor.[26] However, it's uncertain whether the new Arf1 inhibitors specifically target cancer stem cells (CSCs) to induce systemic anti‐tumor immunity due to the ongoing debate about CSC markers and their identity.